# Effect of Bifidobacterium Breve PRL2020 (an Amoxicillin-clavulanate-resistant Strain) on Gastrointestinal Symptoms and Gut Microbiota Composition in Children Treated With Amoxicillin or Amoxicillin/Clavulanate

> **NCT05840588** · NA · COMPLETED · sponsor: **Liaquat University of Medical & Health Sciences** · enrollment: 121 (actual)

## Conditions studied

- Bacterial Infections

## Interventions

- **DRUG:** Antibiotic Treatment
- **DIETARY_SUPPLEMENT:** Probiotic Bifidobacterium breve PRL2020 (Brevicillin®) treatment

## Key facts

- **NCT ID:** NCT05840588
- **Lead sponsor:** Liaquat University of Medical & Health Sciences
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-11-06
- **Primary completion:** 2025-03-31
- **Final completion:** 2025-04-18
- **Target enrollment:** 121 (ACTUAL)
- **Last updated:** 2025-11-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05840588

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05840588, "Effect of Bifidobacterium Breve PRL2020 (an Amoxicillin-clavulanate-resistant Strain) on Gastrointestinal Symptoms and Gut Microbiota Composition in Children Treated With Amoxicillin or Amoxicillin/Clavulanate". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05840588. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*